{
    "ticker": "CYTO",
    "name": "CytomX Therapeutics, Inc.",
    "description": "CytomX Therapeutics, Inc. is a biopharmaceutical company focused on developing a new class of therapeutics known as Probody\u2122 therapeutics. Founded in 2011, CytomX leverages its proprietary technology platform to create targeted cancer therapies that are designed to selectively engage with tumors while minimizing damage to healthy tissue. The company's innovative approach aims to improve the safety and efficacy of cancer treatments. CytomX's lead product candidate, PBK-1, is an investigational drug currently in clinical trials for several types of cancer, including solid tumors. The company partners with leading pharmaceutical organizations to enhance its research and development efforts, bringing together expertise in drug development and cutting-edge science. By focusing on the tumor microenvironment, CytomX is at the forefront of advancing precision medicine in oncology. With a commitment to transforming cancer care, CytomX is dedicated to making a significant impact on patients' lives through innovative therapies that address unmet medical needs.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South San Francisco, California, USA",
    "founded": "2011",
    "website": "https://www.cytomx.com",
    "ceo": "Sean McCarthy",
    "social_media": {
        "twitter": "https://twitter.com/CytomX",
        "linkedin": "https://www.linkedin.com/company/cytomx-therapeutics/"
    },
    "investor_relations": "https://investors.cytomx.com",
    "key_executives": [
        {
            "name": "Sean McCarthy",
            "position": "CEO"
        },
        {
            "name": "Jennifer Ruddock",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Probody Therapeutics",
            "products": [
                "PBK-1",
                "PBK-2"
            ]
        }
    ],
    "seo": {
        "meta_title": "CytomX Therapeutics, Inc. | Innovating Cancer Treatment",
        "meta_description": "Learn about CytomX Therapeutics, Inc., a leader in Probody therapeutics aiming to revolutionize cancer treatment through targeted therapies.",
        "keywords": [
            "CytomX",
            "Probody Therapeutics",
            "Cancer Treatment",
            "Biotechnology",
            "Oncology"
        ]
    },
    "faq": [
        {
            "question": "What is CytomX known for?",
            "answer": "CytomX is known for developing Probody therapeutics that target tumors while sparing healthy tissue."
        },
        {
            "question": "Who is the CEO of CytomX?",
            "answer": "Sean McCarthy is the CEO of CytomX Therapeutics, Inc."
        },
        {
            "question": "Where is CytomX headquartered?",
            "answer": "CytomX is headquartered in South San Francisco, California, USA."
        },
        {
            "question": "What are CytomX's main products?",
            "answer": "CytomX's main product candidates include PBK-1 and PBK-2, which are in various stages of clinical trials."
        },
        {
            "question": "When was CytomX founded?",
            "answer": "CytomX was founded in 2011."
        }
    ],
    "competitors": [
        "BMY",
        "AMGN",
        "REGN",
        "MRNA"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "ABBV",
        "JNJ"
    ]
}